

Jason R Westin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268968/publications.pdf>

Version: 2024-02-01

156
papers

16,891
citations

71004

43
h-index

18400

124
g-index

160
all docs

160
docs citations

160
times ranked

14025
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	1.7	43
2	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
3	A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 74-83.	0.6	4
4	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	2.5	24
5	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. <i>Blood Advances</i> , 2022, 6, 2267-2274.	2.5	6
6	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
7	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	2.5	21
8	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (≥ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
9	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
10	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	13.9	243
11	Always be prepared for success. <i>Blood</i> , 2022, 139, 1928-1930.	0.6	0
12	SIRP β macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. <i>Blood Advances</i> , 2022, 6, 3286-3293.	2.5	3
13	CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. <i>Blood</i> , 2022, 139, 2737-2746.	0.6	60
14	Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 504-512.	0.2	17
15	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. <i>Blood</i> , 2022, 140, 504-515.	0.6	19
16	Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2041-2051.	0.6	1
17	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
18	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	1.7	92

#	ARTICLE	IF	CITATIONS
19	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. <i>British Journal of Haematology</i> , 2021, 192, e38-e42.	1.2	33
20	A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1414-1420.	0.4	5
21	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. <i>Blood</i> , 2021, 137, 1124-1129.	0.6	7
22	Why R-CHOP is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1302-1312.	0.6	5
23	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	0.6	95
24	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	0.6	3
25	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
26	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	9.4	151
27	CRP and ferritin in addition to the EASIX score predict CAR-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	2.5	57
28	Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0
29	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	0.8	37
30	Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K δ/ϵ in relapsed refractory B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3452-3462.	0.6	4
31	Efficacy and safety of CD19-directed CAR cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	2.0	107
32	Innovative Approaches in Untreated DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S183-S185.	0.2	0
33	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	5.1	222
34	The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
35	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. <i>Lancet Haematology</i> , the, 2021, 8, e818-e827.	2.2	14
36	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. <i>Leukemia and Lymphoma</i> , 2021, , 1-11.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	0.6	16
38	A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. <i>Haematologica</i> , 2020, 105, e26-e28.	1.7	18
39	<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. <i>Leukemia and Lymphoma</i> , 2020, 61, 328-336.	0.6	7
40	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	0.6	14
41	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. <i>Nature Medicine</i> , 2020, 26, 1878-1887.	15.2	321
42	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3943-3951.	2.5	69
43	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	2.8	8
44	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	0.8	481
45	ICU Resource Use in Critically Ill Patients following Chimeric Antigen Receptor T-Cell Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1184-1187.	2.5	19
46	Impact of maintenance rituximab in patients with <i>de novo</i> transformed indolent B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2985-2989.	0.6	2
47	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	2.5	134
48	Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3123-3127.	2.5	115
49	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. <i>Leukemia and Lymphoma</i> , 2020, 61, 1380-1387.	0.6	4
50	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2020, 105, 1907-1913.	1.7	23
51	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	2.5	48
52	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<sc>MCL</sc>) -outcomes and mutation profile from venetoclax resistant <sc>MCL</sc> patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
53	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.2	2
54	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43

#	ARTICLE	IF	CITATIONS
55	CAR T-Cells. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 215-233.	0.8	24
56	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	0.6	37
57	Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8003-8003.	0.8	4
58	Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucl. <i>Blood</i> , 2020, 136, 16-17.	0.6	3
59	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019, 24, 219-228.	1.9	30
60	Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. <i>British Journal of Haematology</i> , 2019, 185, 334-338.	1.2	16
61	Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 709-714.	0.2	8
62	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	13.5	138
63	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
64	BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S270-S271.	0.2	1
65	Ibrutinib and lenalidomide: when 1+1 = >2. <i>Blood</i> , 2019, 134, 996-998.	0.6	3
66	A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 800-804.	0.7	1
67	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
68	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	0.8	2
69	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 447-455.	0.4	31
70	Lenalidomide plus rituximab (R ²) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. <i>British Journal of Haematology</i> , 2019, 185, 874-882.	1.2	37
71	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
72	Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S20-S21.	2.0	28

#	ARTICLE	IF	CITATIONS
73	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
74	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
75	Frontline antibiotic therapy for early-stage <i>Helicobacter pylori</i> negative gastric MALT lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E150-E153.	2.0	7
76	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019, 3, 2230-2236.	2.5	59
77	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
78	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 789-796.	0.6	12
79	Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival?. <i>Annals of Hematology</i> , 2019, 98, 1169-1176.	0.8	11
80	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
81	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
82	Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 765-765.	0.6	23
83	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	0.6	3
84	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	0.6	8
85	Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results. <i>Blood</i> , 2019, 134, 1581-1581.	0.6	14
86	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	0.6	24
87	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
88	Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. <i>Clinical Cancer Research</i> , 2018, 24, 3967-3980.	3.2	69
89	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 2896-2903.	0.6	12
90	University of Chicago phase II consortium trial of selumetinib (<sc>MEK</sc>) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018, 181, 264-267.	1.2	4

#	ARTICLE	IF	CITATIONS
91	Chimeric antigen receptor T-cell therapy "assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	12.5	1,659
92	Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e103-e108.	0.2	3
93	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq1 1 0.784314 rgBT /O 863-870.	0.6	22
94	Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. British Journal of Haematology, 2018, 182, 718-723.	1.2	1
95	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
96	Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget, 2018, 9, 28897-28902.	0.8	26
97	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Advances, 2018, 2, 1334-1343.	2.5	23
98	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). British Journal of Haematology, 2018, 182, 404-411.	1.2	50
99	End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. Blood, 2018, 132, 4192-4192.	0.6	46
100	Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study. Blood, 2018, 132, 447-447.	0.6	3
101	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	0.6	81
102	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. Blood, 2018, 132, 1684-1684.	0.6	28
103	The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS ONE, 2018, 13, e0191461.	1.1	25
104	Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget, 2018, 9, 346-360.	0.8	14
105	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist, 2017, 22, 549-553.	1.9	4
106	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 2833-2844.	0.6	13
107	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood, 2017, 130, 472-477.	0.6	65
108	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head and Neck, 2017, 39, 1095-1100.	0.9	87

#	ARTICLE	IF	CITATIONS
109	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. British Journal of Haematology, 2017, 177, 263-270.	1.2	14
110	The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology, 2017, 176, 750-758.	1.2	78
111	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Advances in Radiation Oncology, 2017, 2, 370-380.	0.6	5
112	Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. American Journal of Surgical Pathology, 2017, 41, 1309-1321.	2.1	32
113	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Modern Pathology, 2017, 30, 1688-1697.	2.9	46
114	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood, 2017, 130, 1800-1808.	0.6	1,084
115	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	13.9	3,865
116	Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood, 2017, 130, 995-1006.	0.6	84
117	Dose-adjusted EPOCH and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology, 2017, 179, 851-854.	1.2	15
118	Dose adjusted EPOCH and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology, 2017, 179, 503-506.	1.2	9
119	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	0.8	1
120	What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 483-487.	0.2	1
121	Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e65-e70.	0.2	5
122	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. British Journal of Haematology, 2016, 172, 80-88.	1.2	82
123	Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer, 2016, 122, 3145-3151.	2.0	61
124	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum Î2-microglobulin level in patients with diffuse large B-cell lymphoma: a new prognostic model. British Journal of Haematology, 2016, 175, 290-299.	1.2	31
125	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncology, 2016, 2, 1065.	3.4	36
126	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 122-128.	0.2	12

#	ARTICLE	IF	CITATIONS
127	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 48-56.	5.1	189
128	The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin) Tj ETQq0 0 0 rgBT /Overlock 10 Blood, 2016, 128, 1833-1833.	0.6	1
129	Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e272-e274.	1.7	17
130	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 113-121.	0.4	50
131	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.4	110
132	Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review. <i>Clinical Imaging</i> , 2015, 39, 525-528.	0.8	22
133	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 122-129.	0.4	37
134	Busting robustness: using cancer's greatest strength to our advantage. <i>Future Oncology</i> , 2015, 11, 73-77.	1.1	7
135	A clinician's guide to double hit lymphomas. <i>British Journal of Haematology</i> , 2015, 168, 784-795.	1.2	54
136	A Single Case of Rosai-Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. <i>Frontiers in Oncology</i> , 2014, 4, 297.	1.3	10
137	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 69-77.	5.1	518
138	Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburger. <i>British Journal of Haematology</i> , 2014, 165, 146-147.	1.2	2
139	Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 335-342.	0.2	72
140	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1311-1318.	5.1	239
141	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , 2014, 166, 891-901.	1.2	310
142	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 1019-1026.	5.1	246
143	Accelerated therapeutic progress in diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 541-556.	0.8	25
144	Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 177-184.	1.2	14

#	ARTICLE	IF	CITATIONS
145	Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 99-105.	0.2	25
146	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620.	1.2	23
147	R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 537-540.	0.6	3
148	Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula. <i>Case Reports in Medicine</i> , 2012, 2012, 1-4.	0.3	6
149	It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2549-2555.	1.9	48
150	A Multidisciplinary Approach to Cancer. , 2012, , 13-16.		0
151	Steroid-Refractory Acute GVHD: Predictors and Outcomes. <i>Advances in Hematology</i> , 2011, 2011, 1-8.	0.6	146
152	Vive la Résistance: stem cells in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 944-945.	0.6	0
153	De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 161-163.	0.6	11
154	Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 218-224.	1.2	23
155	Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.. <i>Blood</i> , 2009, 114, 3922-3922.	0.6	0
156	Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 0, , .	2.5	1